摘要
目的探索坎地沙坦和氟桂利嗪在预防性治疗偏头痛中的价值。方法 132例偏头痛患者,随机分成A组和B组,每组66例。A组患者给予坎地沙坦治疗,B组患者给予氟桂利嗪治疗,对比两组患者的头痛发作状况、头痛指数、不良反应发生率。结果治疗前两组患者头痛发作频率、头痛发作时间及头痛发作强度对比差异无统计学意义(P>0.05);经过3个月预防性治疗后,两组患者头痛发作频率、头痛发作时间及头痛发作强度均有明显改善(P<0.05);两组患者治疗后各指标对比差异无统计学意义(P>0.05)。两组患者治疗后的头痛指数较治疗前明显降低(P<0.05);两组患者治疗后头痛指数对比差异无统计学意义(P>0.05)。A组患者的不良反应发生率为3.03%,B组患者不良反应发生率为12.12%,A组患者不良反应发生率明显低于B组(P<0.05)。结论坎地沙坦和氟桂利嗪在预防性治疗偏头痛上均能起到较为明显的治疗效果,减轻头痛症状,而坎地沙坦的不良反应少,安全性高,值得在临床上推广应用。
Objective To investigate the value of candesartan and flunarizine for preventive treatment of migraine.Methods A total of 132 migraine patients were randomly divided into group A and group B,with 66 cases in each group.Group A was treated with candesartan,and group B was treated with flunarizine.Comparison were made on headache attack status,headache index and incidence of adverse reactions in two groups.Results Before treatment,both groups had no statistically significant difference in headache attack frequency,headache attack time and headache attack intensity（P〈0.05）.After 3 months of preventive treatment,both groups had better headache attack frequency,headache attack time and headache attack intensity（P〉0.05）.Both groups had no statistically significant difference in indexes after treatment（P〈0.05）.Both groups had lower headache index than before treatment（P〈0.05）.Both groups had no statistically significant difference in headache index after treatment（P〈0.05）.Group A had incidence of adverse reactions as 3.03%,which were 12.12% in group B,group A had obviously lower incidence of adverse reactions than group B（P〈0.05）.Conclusion Both candesartan and flunarizine shows obvious treatment effect in treating migraine and reducing headache symptom,but candesartan has less adverse reactions and higher safety.So it is worthy of clinical promotion and application.
出处
《中国实用医药》
2017年第22期102-104,共3页
China Practical Medicine
